Wide Ranks

ADPT

Adaptive Biotechnologies Corpor

5.73

Top Statistics
Market Cap 845 M Forward PE -6.71 Revenue Growth 22.50 %
Current Ratio 3.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -110.13 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.62 Enterprise / Revenue 4.66 Price To Sales Trailing12 Months 4.77
Profitability
Profit Margins -110.13 % Operating Margins -70.28 %
Balance Sheet
Total Cash 243 M Total Cash Per Share 1.65 Total Debt 224 M
Total Debt To Equity 100.42 Current Ratio 3.52 Book Value Per Share 1.52
All Measures
Short Ratio 786.00 % Message Board Id finmb_100147173 Fax 206 659 0667
Shares Short Prior Month 9 M Return On Equity -0.6676 City Seattle
Uuid 567cfea8-637f-3416-be65-3a350f304bc9 Previous Close 5.68 First Trade Date Epoch Utc 1 B
Book Value 1.52 Beta 1.45 Total Debt 224 M
Volume 823001 Price To Book 3.78 Fifty Two Week Low 2.28
Total Cash Per Share 1.65 Total Revenue 177 M Shares Short Previous Month Date 1 B
Target Median Price 7.00 Audit Risk 4 Max Age 86400
Recommendation Mean 1.88 Sand P52 Week Change 0.3133 Operating Margins -70.28 %
Target Mean Price 7.42 Net Income To Common -195240992 Short Percent Of Float 0.0714
Implied Shares Outstanding 147 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 243 M
Next Fiscal Year End 1 B Revenue Per Share 1.21 Held Percent Insiders 0.0193
Ebitda Margins -82.89 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 5.68
Target Low Price 5.50 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.03
Open 5.72 Free Cashflow -44016248 State WA
Dividend Yield 0.00 % Return On Assets -0.1637 Time Zone Short Name EST
Board Risk 9 Trailing Eps -1.34 Day Low 5.53
Address1 1165 Eastlake Avenue East Shares Outstanding 147 M Compensation Risk 9
Price Hint 2 Target High Price 10.00 Website https://www.adaptivebiotech.com
52 Week Change 0.3082 Average Volume 1 M Forward Eps -0.9400
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 325.70 %
Is_sp_500 False Regular Market Day High 5.82 Profit Margins -110.13 %
Debt To Equity 100.42 Fifty Two Week High 6.70 Day High 5.82
Shares Short 8 M Regular Market Open 5.72 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 4.66 Revenue Growth 22.50 %
Shares Percent Shares Out 0.0556 Operating Cashflow -109653000 Currency USD
Time Zone Full Name America/New_York Market Cap 845 M Is_nasdaq_100 False
Zip 98109 Quote Type EQUITY Industry Biotechnology
Long Name Adaptive Biotechnologies Corporation Overall Risk 8 Regular Market Day Low 5.53
Held Percent Institutions 0.9397 Current Price 5.73 Enterprise To Ebitda -5.62
Financial Currency USD Current Ratio 3.52 Gross Margins -2.75 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 76 M Two Hundred Day Average 4.03 Governance Epoch Date 1 B
Enterprise Value 826 M Price To Sales Trailing12 Months 4.77 Forward PE -6.71
Regular Market Volume 823001 Ebitda -146946000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).

The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.

Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.

The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.

Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.